Editorial: Resolution of non-alcoholic-steatohepatitis. More than one drug needed?

Current Vascular Pharmacology

Volumn 14, Issue 4, 2016, Pages 313-315

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT;

CARDIOVASCULAR DISEASE; DRUG EFFICACY; EDITORIAL; ENZYME ACTIVITY; FATTY LIVER; FIBROSIS; HUMAN; LIVER BIOPSY; LIVER INJURY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; POST HOC ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT REDUCTION; COMBINATION DRUG THERAPY; PROCEDURES;

DRUG THERAPY, COMBINATION; FATTY LIVER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIRAGLUTIDE; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84978258582     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114999160513150605     Document Type: Editorial

References (17)

1. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, doubleblind, randomised, placebo-controlled phase 2 study. Lancet 2015 Nov 19 pii: S0140-6736(15)00803-X. [Epub ahead of print].
2. Tison GH, Blaha MJ, Nasir K, Blumenthal RS, Szklo M, Ding J, Budoff MJ. Relation of Anthropometric Obesity and Computed Tomography Measured Nonalcoholic Fatty Liver Disease (from the Multiethnic Study of Atherosclerosis). Am J Cardiol 2015; 116: 541-6.
3. Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
4. Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010(9756): 376: 1916-22.
5. Bays H, Cohen DE, Chalasani N, Harrison SA. The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8(3 Suppl): S47-57.
6. Athyros VG, Giouleme O, Ganotakis ES, et al. for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT Study. Arch Med Sci 2011; 7: 796-805.
7. Tikkanen MJ, Fayyad R, Faergeman O, et al. IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-52.
8. Kargiotis K, Katsiki N, Athyros VG, et al. Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. Curr Vasc Pharmacol 2014; 12: 505-11.
9. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-7868.
10. Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12.
11. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins and non-alcoholic steatohepatitis. J Hepatol 2016; 64: 241-2.
12. Dongiovanni P, Pihlajamaki J, Romeo S, Valenti L. Reply to "Statin treatment for non-alcoholic steatohepatitis." J Hepatol 2016; 6: 242-3.
13. Athyros VG, Mikhailidis DP. Therapy: Caloric and fat intake in statin users. Nat Rev Endocrinol. 2014; 10: 450-1.
14. Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64: 471-475.
15. Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and new-onset diabetes mellitus-a matter for debate. Nat Rev Endocrinol. 2012; 8: 133-4.
16. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Statins and Type 2 Diabetes Mellitus: An Update After 1 Year. Curr Pharm Des. 2016 Jan 24. [Epub ahead of print] PubMed PMID: 26806344.
17. Athyros VG, Tziomalos K, Daskalopoulos GN, Karagiannis A, Mikhailidis DP. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011; 43: 167-71.